Cannabix and University of Florida make significant strides in developing benchtop FAIMS technology into a portable Cannabix Marijuana Breathalyzer


Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”)
developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to release images of its Beta 2.0 Cannabix Marijuana Breathalyzer. New images of the device can be viewed at www.cannabixtechnologies.com.
Cannabix has been using a methodical iterative product development process to develop its marijuana breathalyzer.  Using this method, the product is developed in several prototype stages with each stage used to advance the product to subsequent stages.   Cannabix has systematically moved the development of the Cannabix Marijuana Breathalyzer from a concept stage to its Beta 2.0 prototype. The following is a chronology of development highlights:

  • August 2015-Cannabix entered into a research and option agreement to develop a cutting-edge breath detection sensor based upon high-field ion mobility coupled with mass spectrometry in collaboration with the Yost Research Group at the University of Florida.  The Yost Research Group, a world leader and pioneer in the development of high-field asymmetric waveform ion mobility spectrometry, known as FAIMS.  Cannabix and The Yost Research Group began working together to identify Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) in ultra low ranges using highly a sensitive FAIMS-mass spectrometer benchtop system. The Company entered into a definitive license agreement with the University of Florida for US Patent 8,237,118 in the summer of 2016 which provided the Company exclusive worldwide rights in the area of breath analysis of controlled substances.
  • June 2016-Cannabix Scientists and Dr. Rick Yost at the University of Florida developed a standalone desktop-sized “Beta 1.0” FAIMS based device with a proprietary configurable high voltage power supply which operated with conventional power sources. The FAIMS cell employed in “Beta 1.0” device was 4X smaller than the prior benchtop version and had achieved a 10X reduction in power supply size, which allowed for a drastically smaller footprint.  The Beta 1.0 included a power supply that was readily configurable for ongoing testing and was designed to integrate with a non-radioactive ionization source.
  • October 19, 2016- Cannabix developed its “Beta 2.0” Cannabix Marijuana Breathalyzer with major advances in the design and size of the device, including:  greater sensitivity, improved performance by the square waveform generator and a much smaller size for all components.  The Beta 2.0 design included features to allow for the addition of a rechargeable battery and touch screen and the device is approximately 10 times smaller than the Beta 1.0 device. Preliminary lab tests of the FAIMS device coupled with quadrupole ion trap mass spectrometry have shown lower levels of detection for THC standards than were achieved in past testing.
  • November 11, 2016- Cannabix provides the first images of the Cannabix Marijuana Breathalyzer “Beta 2.0” device.  Images show components housed in a durable compact black box which has been reduced in size to be a portable device. The device encompasses the latest chip technology to improve speed performance, FAIMS detection technology, conventional battery and updated square wave generator. Cannabix believes that the Beta 2.0 Cannabix Marijuana Breathalyzer which utilizes FAIMS detection technology is the most sensitive and scientifically proven method of detection of volatile compounds found at trace levels in exhaled breath.

Read full press release.
Click here to visit the Cannabix Technologies Inc. website.


The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less